Gregory Renza
Stock Analyst at Truist Financial
Total Price Targets
27
Stocks Covered
15
Sectors
Healthcare
Most Recent
Apr 8, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Gregory Renza
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | $155.00 | $132.04 | +17.4% | 2 | Apr 8, 2026 |
| FULC | Fulcrum Therapeutics, Inc. | $17.00 | $7.37 | +130.8% | 4 | Feb 24, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $60.00 | $28.27 | +112.3% | 3 | Jan 6, 2026 |
| AGIO | Agios Pharmaceuticals, Inc. | $38.00 | $28.15 | +35.0% | 2 | Dec 24, 2025 |
| ADCT | ADC Therapeutics S.A. | $5.00 | $3.82 | +30.9% | 1 | Dec 3, 2025 |
| CGON | CG Oncology, Inc. Common stock | $62.00 | $66.29 | -6.5% | 1 | Nov 24, 2025 |
| XNCR | Xencor, Inc. | $18.00 | $12.88 | +39.8% | 2 | Oct 27, 2025 |
| NRIX | Nurix Therapeutics, Inc. | $29.00 | $16.83 | +72.3% | 3 | Oct 22, 2025 |
| CRMD | CorMedix Inc. | $22.00 | $7.82 | +181.5% | 2 | Oct 21, 2025 |
| JAZZ | Jazz Pharmaceuticals plc | $151.00 | $202.38 | -25.4% | 1 | Aug 28, 2025 |
| VRDN | Viridian Therapeutics, Inc. | $22.00 | $13.41 | +64.1% | 2 | Sep 13, 2024 |
| INO | Inovio Pharmaceuticals, Inc. | $8.00 | $1.12 | +614.3% | 1 | Aug 9, 2024 |
| AMGN | Amgen Inc. | $332.00 | $328.69 | +1.0% | 1 | Jun 14, 2024 |
| CATX | Perspective Therapeutics, Inc. | $3.00 | $3.90 | -23.0% | 1 | Jun 14, 2024 |
| VSTM | Verastem, Inc. | $5.00 | $5.86 | -14.7% | 1 | Apr 15, 2022 |
Recent Activity
- Apr 8, 2026— Set$155.00price target onGILD(Gilead Sciences, Inc.)
- Feb 24, 2026— Set$17.00price target onFULC(Fulcrum Therapeutics, Inc.)
- Jan 6, 2026— Set$60.00price target onIDYA(IDEAYA Biosciences, Inc.)
- Dec 24, 2025— Set$38.00price target onAGIO(Agios Pharmaceuticals, Inc.)
- Dec 3, 2025— Set$5.00price target onADCT(ADC Therapeutics S.A.)
- Nov 24, 2025— Set$140.00price target onGILD(Gilead Sciences, Inc.)
- Nov 24, 2025— Set$62.00price target onCGON(CG Oncology, Inc. Common stock)
- Oct 27, 2025— Set$18.00price target onXNCR(Xencor, Inc.)
- Oct 22, 2025— Set$29.00price target onNRIX(Nurix Therapeutics, Inc.)
- Oct 21, 2025— Set$22.00price target onCRMD(CorMedix Inc.)
- Sep 9, 2025— Set$38.00price target onIDYA(IDEAYA Biosciences, Inc.)
- Aug 28, 2025— Set$151.00price target onJAZZ(Jazz Pharmaceuticals plc)
- Sep 13, 2024— Set$22.00price target onVRDN(Viridian Therapeutics, Inc.)
- Sep 12, 2024— Set$4.00price target onFULC(Fulcrum Therapeutics, Inc.)
- Sep 3, 2024— Set$15.00price target onFULC(Fulcrum Therapeutics, Inc.)
- Aug 9, 2024— Set$8.00price target onINO(Inovio Pharmaceuticals, Inc.)
- Jul 10, 2024— Set$61.00price target onIDYA(IDEAYA Biosciences, Inc.)
- Jun 27, 2024— Set$26.00price target onNRIX(Nurix Therapeutics, Inc.)
- Jun 14, 2024— Set$31.00price target onXNCR(Xencor, Inc.)
- Jun 14, 2024— Set$3.00price target onCATX(Perspective Therapeutics, Inc.)
Frequently Asked Questions
Who is Gregory Renza?
Gregory Renza is a stock analyst at Truist Financial covering 15 stocks primarily in Healthcare. They have issued 27 price targets since Apr 15, 2022.
What stocks does Gregory Renza cover?
Gregory Renza currently covers 15 stocks, including FULC, IDYA, NRIX, GILD, AGIO.
What is Gregory Renza's latest price target?
Gregory Renza's most recent price target was $155.00 on GILD (Gilead Sciences, Inc.), set on Apr 8, 2026.
What is Gregory Renza's highest price target?
Gregory Renza's highest issued price target is $332.00 on AMGN, set on Jun 14, 2024.
More Analysts at Truist Financial
Coverage based on publicly published price targets. Not investment advice.